Organon Enters into Global License Agreement to Commercialize Daré Bioscience's ... - BioSpace

Retrieved on: 2022-03-31 11:26:10

Tags for this article:

Articles

Schering-Plough

Human reproduction

Medical specialties

Communication

Forward-looking statement

Click the tags to see associated articles and topics

Organon Enters into Global License Agreement to Commercialize Daré Bioscience's ... - BioSpace. View article details on HISWAI: https://www.biospace.com/article/releases/organon-enters-into-global-license-agreement-to-commercialize-dare-bioscience-s-xaciato-clindamycin-phosphate-vaginal-gel-2-percent-fda-approved-treatment-for-females-12-and-older-with-bacterial-vaginosis-bv-/

Excerpt

... a global women's healthcare company, and DARÉ Bioscience (NASDAQ: DARE), a leader in women's health innovation, today announced they have ...

Article found on: www.biospace.com

View Original Article